Evercore ISI Group Maintains Outperform on Longboard Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Josh Schimmer has reiterated an 'Outperform' rating for Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a price target of $80.
August 26, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group has reiterated its 'Outperform' rating for Longboard Pharmaceuticals, maintaining a price target of $80, indicating confidence in the company's future performance.
The reaffirmation of an 'Outperform' rating and a high price target of $80 by a reputable analyst suggests a positive outlook for Longboard Pharmaceuticals. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100